Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Benitec Exchange Licensing Rights for RNAi Technologies

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and Benitec have exchanged licensing options for RNA interference intellectual property, the companies said yesterday.

 

Under the agreement, Benitec and its licensees have the option to non-exclusively license expressed RNAi technology from Alnylam. Benitec also has the right to obtain up to five exclusive InterfeRx licenses from Alnylam to develop synthetic RNAi therapeutics against specific targets.

 

Alnylam has the option to non-exclusively license technology covering expressed RNAi and synthetic siRNAs from Benitec.

 

If either company exercises its options, the other company will receive license fees and be eligible for milestone payments and royalties on any products developed under the licenses.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.